Abstract: An apparatus for installing or replacing license software such as in a device or secure digital card of a controller. The apparatus may have a door that is situated in a base of the controller. The door may slide down to provide an opening that permits access to a place, an area or receptacle that holds the card. The door may not necessarily be open-able until the controller is removed from a panel, a din rail, or some other structure, where a removal of power has to occur. The door may be designed so that it blends in with the base in that just qualified installers are aware of how to find the door for access to the card. To close the door, the card needs to be fully installed before the door can be closed. The door may be designed with hook features to prevent its removal from the controller base.

Abstract: An apparatus for installing or replacing license software such as in a device or secure digital card of a controller. The apparatus may have a door that is situated in a base of the controller. The door may slide down to provide an opening that permits access to a place, an area or receptacle that holds the card. The door may not necessarily be open-able until the controller is removed from a panel, a din rail, or some other structure, where a removal of power has to occur. The door may be designed so that it blends in with the base in that just qualified installers are aware of how to find the door for access to the card. To close the door, the card needs to be fully installed before the door can be closed. The door may be designed with hook features to prevent its removal from the controller base.

Abstract: Glypican 5 is shown for the first time to have a role in proliferation of cancer cells, including tumours which do not show chromosomal amplification at 13q31. The use of glypican 5 (GPC5) antagonists and binding agents for the treatment of cancer, particularly rhabdomyosarcoma and breast cancer, is disclosed.

Abstract: Glypican 5 is shown for the first time to have a role in proliferation of cancer cells, including tumors which do not show chromosomal amplification at 13q31. The use of glypican 5 (GPC5) antagonists and binding agents for the treatment of cancer, particularly rhabdomyosarcoma and breast cancer, is disclosed.

Abstract: Glypican 5 is shown for the first time to have a role in proliferation of cancer cells, including tumours which do not show chromosomal amplification at 13q31. The use of glypican 5 (GPC5) antagonists and binding agents for the treatment of cancer, particularly rhabdomyosarcoma and breast cancer, is disclosed.

Abstract: A gas-powered, durable, needle-less hypodermic jet injection device (10, 210) includes a hand-held injector (12, 212) which receives into an injection cylinder a volume of liquid medication to be injected in the form of a high velocity jet capable of penetrating the skin without the use of a hypodermic needle. The injection device provides an injection orifice, and an injection piston. Forceful movement of the injection piston causes a high velocity injection jet of liquid medication to be expelled from the injection cylinder via the injection orifice. The injection device includes features which improve its usability, particularly for users with hands that are possibly weak, feeble, or arthritic, for example; and also includes additional features which improve manufacturability, durability, and cost effectiveness of the device.

Abstract: A gas-powered, durable, needle-less hypodermic jet injection device (10, 210) includes a hand-held injector (12, 212) which receives into an injection cylinder a volume of liquid medication to be injected in the form of a high velocity jet capable of penetrating the skin without the use of a hypodermic needle. The injection device provides an injection orifice, and an injection piston. Forceful movement of the injection piston causes a high velocity injection jet of liquid medication to be expelled from the injection cylinder via the injection orifice. The injection device includes features which improve its usability, particularly for users with hands that are possibly weak, feeble, or arthritic, for example; and also includes additional features which improve manufacturability, durability, and cost effectiveness of the device.